Drug Trial Radar · NCT01207440
Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)
Last checked: Nov 20, 2026Latest source record: Feb 2, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
449
Actual
Start
Sep 30, 2010
Primary completion
Dec 20, 2018
Study completion Jan 17, 2019
Sponsor
- Lead sponsor
- Ariad PharmaceuticalsTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Sep 23, 2010
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the efficacy of ponatinib in patients with chronic myeloid leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast phase (BP) or with philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) who either are resistant or intolerant to either dasatinib or nilotinib, or have the (T)hreonine-315-(I)soleucine (T315I) mutation.
Conditions
- Chronic Myeloid Leukemia
- Ph+ Acute Lymphoblastic Leukemia
Interventions
PonatinibDrug
Ponatinib tablets.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of CP-CML Participants With Major Cytogenetic Response (MCyR)Time frame: Up to 12 months after initiation of study treatment
- Percentage of AP-CML Participants With Major Hematologic Response (MaHR)Time frame: Up to 6 months after initiation of study treatment
- Percentage of BP-CML/Ph+ ALL Participants With MaHRTime frame: Up to 6 months after initiation of study treatment
Locations
42 sites in 11 countries. Site status is shown where the registry gives one.
Royal North Shore Hospital
St Leonards, New South Wales, Australia
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Alfred Hospital
Box Hill, Victoria, Australia
Peter MacCallum Cancer Centre
East Melbourne, Victoria, Australia
UCL Bruxelles
Brussels, Belgium
UZ Leuven
Leuven, Belgium
Institut Bergonie
Bordeaux, France
Hopital Andre Mignot
Le Chesnay, France
Hopital Claude Huriez CHRU
Lille, France
Chu Brabois
Nancy, France
Hopital Archet
Nice, France
Hopital St. Louis
Paris, France
Hopital Edouard Herriot
Pierre-Bénite, France
Entre Hospitalier Universitaire
Poitiers, France
Hopital de Purpan
Toulouse, France
Charite - Universitatsmedizin Berlin,
Berlin, Germany
Klinikum der Goethe Universitat,
Frankfurt, Germany
Universitatsklinikum Jena
Jena, Germany
University of Heidelberg
Mannheim, Germany
III. Med. Klinik und Poliklinik
München, Germany
Universita di Bologna
Bologna, Italy
University of Modena
Modena, Italy
University of Milano Bicocca
Monza, Italy
University of Turin
Orbassano (TO), Italy
University Tor Vergata
Roma, Italy
VU University Medical Center
Amsterdam, Netherlands
University Medical Center Groeningen
Groningen, Netherlands
Singapore General Hospital
Singapore, Singapore
The Catholic University of Korea, Seoul St.Mary's Hospital
Seoul, South Korea
Hospital Clinic
Barcelona, Spain
La Paz
Madrid, Spain
Hospital Universitario de Salamanca
Salamanca, Spain
Hospital Clinico of Valencia
Valencia, Spain
Lund University
Lund, Sweden
Karolinska Hospital
Stockholm, Sweden
University Hospital Uppsala
Uppsala, Sweden
Gartnavel General Hospital
Glasgow, United Kingdom
Royal Liverpool University Hospital
Liverpool, United Kingdom
Hammersmith Hospital
London, United Kingdom
Showing 40 of 42 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.